Enhanced 5-HT2C receptor signaling is associated with haloperidol-induced "early onset" vacuous chewing in rats: Implications for antipsychotic drug therapy

Psychopharmacology

Volumn 182, Issue 1, 2005, Pages 84-94

  Wolf, William A ^a,b   Bieganski, Gerald J ^a   Guillen, Veronica ^a   Mignon, Laurence ^c  

^a HINES VA HOSPITAL   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antipsychotic; Basal ganglia; Extrapyramidal side effects; Phospholipase C; Serotonin

Indexed keywords

(3 CHLOROPHENYL)PIPERAZINE; GUANOSINE TRIPHOSPHATE; HALOPERIDOL; ISOPROTEIN; NEUROLEPTIC AGENT; PHOSPHOLIPASE C; RADIOLIGAND; SEROTONIN 2C AGONIST; SEROTONIN 2C RECEPTOR; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BEHAVIOR; BINDING AFFINITY; BIOCHEMISTRY; CONTROLLED STUDY; CORPUS STRIATUM; DOWN REGULATION; DRUG EFFECT; DRUG MEGADOSE; DRUG WITHDRAWAL; ENZYME ACTIVITY; FACE; FOLLOW UP; LOW DRUG DOSE; MALE; MASTICATION; MOUTH; MOVEMENT (PHYSIOLOGY); NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN LOCALIZATION; RAT; SCORING SYSTEM; SIGNAL TRANSDUCTION; ANIMAL; BRAIN MAPPING; MICROINJECTION; REINFORCEMENT; SPRAGUE DAWLEY RAT; STEREOTYPY;

ANIMALS; ANTIPSYCHOTIC AGENTS; BRAIN MAPPING; HALOPERIDOL; MALE; MASTICATION; MICROINJECTIONS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, SEROTONIN, 5-HT2C; REINFORCEMENT SCHEDULE; SIGNAL TRANSDUCTION; STEREOTYPED BEHAVIOR;

EID: 25844531048     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00213-005-0033-4     Document Type: Article

References (70)

1. Battaglia G, Shannon M, Titeler M (1984) Guanyl nucleotide and divalent cation regulation of cortical S2 serotonin receptors. J Neurochem 43:1213-1219
2. 2C receptor systems. Mol Pharmacol 55:863-872
3. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254
4. Branchek T, Adham N, Macchi M, Kao HT, Hartig PR (1990) [3H]-DOB(4-bromo-2,5-dimethoxyphenylisopropylamine) and [3H] ketanserin label two affinity states of the cloned human 5-hydroxytryptamine2 receptor. Mol Pharmacol 38:604-609
5. Carlson BB, Wisniecki A, Salamone JD (2003) Local injections of the 5-hydroxytryptamine antagonist mianserin into substantia nigra pars reticulata block tremulous jaw movements in rats: studies with a putative model of parkinsonian tremor. Psychopharmacology (Berl) 165:229-237
6. Casey DE (2004) Pathophysiology of antipsychotic drug-induced movement disorders. J Clin Psychiatry 65(Suppl 9):25-28
7. 2C receptor protein in the rat CNS. Neuropharmacology 39:123-132
8. Cooper WO, Hickson GB, Fuchs C, Arbogast PG, Ray WA (2004) New users of antipsychotic medications among children enrolled in TennCare. Arch Pediatr Adolesc Med 158:753-759
9. De Deurwaerdere P, Chesselet MF (2000) Nigrostriatal lesions alter oral dyskinesia and c-Fos expression induced by the serotonin agonist 1-(m-chlorophenyl)piperazine in adult rats. J Neurosci 20:5170-5178
10. 2C receptor inhibits in vivo dopamine release in the rat striatum and nucleus accumbens. J Neurosci 24:3235-3241
11. 2C/2B receptors enhances mesolimbic and mesostriatal dopaminergic function: a combined in vivo electrophysiological and microdialysis study. Neuroscience 91:587-597
12. 2C-induced oral dyskinesia. Neuroscience 72:117-128
13. 2C receptor messenger RNA in the basal ganglia of adult rats. J Comp Neurol 384:233-247
14. Egan MF, Hyde TM, Kleinman JE, Wyatt RJ (1995) Neuroleptic-induced vacuous chewing movements in rodents: incidence and effects of long-term increases in haloperidol dose. Psychopharmacology (Berl) 117:74-81
15. Egan MF, Hurd Y, Ferguson J, Bachus SE, Hamid EH, Hyde TM (1996) Pharmacological and neurochemical differences between acute and tardive vacuous chewing movements induced by haloperidol. Psychopharmacology (Berl) 127:337-345
16. 2B receptor antagonist with improved affinity, selectivity, and oral activity. J Med Chem 38: 2524-2530
17. Glennon RA, Seggel MR, Soine WH, Herrick-Davis K, Lyon RA, Titeler M (1988) [125I]-1-(2,5-dimethoxy-4-iodophenyl)-2-amino-propane: an iodinated radioligand that specifically labels the agonist high-affinity state of 5-HT2 serotonin receptors. J Med Chem 31:5-7
18. Gong L, Kostrzewa RM (1992) Supersensitized oral responses to a serotonin agonist in neonatal 6-OHDA-treated rats. Pharmacol Biochem Behav 41:621-623
19. Gong L, Kostrzewa RM, Fuller RW, Perry KW (1992) Supersensitization of the oral response to SKF 38393 in neonatal 6-OHDA-lesioned rats is mediated through a serotonin system. J Pharmacol Exp Ther 261:1000-1007
20. Gong L, Kostrzewa RM, Perry KW, Fuller RW (1993) Dose-related effects of a neonatal 6-OHDA lesion on SKF 38393- and m-chlorophenylpiperazine-induced oral activity responses of rats. Brain Res Dev Brain Res 76:233-238
21. Hartig P, Kao HT, Macchi M, Adham N, Zgombick J, Weinshank R, Branchek T (1990) The molecular biology of serotonin receptors. An overview. Neuropsychopharmacology 3:335-347
22. 2C receptors. J Pharmacol Exp Ther 295:226-232
23. Holloman LC, Marder SR (1997) Management of acute extrapyramidal effects induced by antipsychotic drugs. Am J Health-Syst Pharm 54:2461-2477
24. Janno S, Holi M, Tuisku K, Wahlbeck K (2004) Prevalence of neuroleptic-induced movement disorders in chronic schizophrenia inpatients. Am J Psychiatry 161:160-163
25. 2A receptor ligand. Naunyn-Schmiedeberg's Arch Pharmacol 354:205-209
26. Kane JM (2004) Tardive dyskinesia rates with atypical antipsychotics in adults: prevalence and incidence. J Clin Psychiatry 65 (Suppl 9):16-20
27. Kapur S (1996) 5-HT2 antagonism and EPS benefits: is there a causal connection? Psychopharmacology (Berl) 124:35-39
28. Kapur S, Seeman P (2001) Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: a new hypothesis. Am J Psychiatry 158:360-369
29. Kapur S, Wadenberg ML, Remington G (2000) Are animal studies of antipsychotics appropriately dosed? Lessons from the bedside to the bench. Can J Psychiatry 45:241-246
30. Kasckow JW, Mulchahey JJ, Mohamed S (2004) The use of novel antipsychotics in the older patient with neurodegenerative disorders in the long-term care setting. J Am Med Dir Assoc 5:242-248
31. Kenakin T (2004) Principles: receptor theory in pharmacology. Trends Pharmacol Sci 25:186-192
32. Kuoppamaki M, Seppala T, Syvalahti E, Hietala J (1993) Chronic clozapine treatment decreases 5-hydroxytryptamine1C receptor density in the rat choroid plexus: comparison with haloperidol. J Pharmacol Exp Ther 264:1262-1267
33. 2C receptors after chronic treatment with clozapine, chlorpromazine and three putative atypical antipsychotic drugs. Neuropsychopharmacology 13:139-150
34. Leysen JE, Janssen PM, Megens AA, Schotte A (1994) Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity. J Clin Psychiatry 55(Suppl):5-12
35. 2A serotonin receptors selectively in primate brain. Neuropharmacology 37:1147-1158
36. Lyon RA, Davis KH, Titeler M (1987) 3H-DOB (4-bromo-2,5- dimethoxyphenylisopropylamine) labels a guanyl nucleotide-sensitive state of cortical 5-HT2 receptors. Mol Pharmacol 31:194-199
37. Marchese G, Casu MA, Bartholini F, Ruiu S, Saba P, Gessa GL, Pani L (2002) Sub-chronic treatment with classical but not atypical antipsychotics produces morphological changes in rat nigro-striatal dopaminergic neurons directly related to "early onset" vacuous chewing. Eur J Neurosci 15:1187-1196
38. Marchese G, Bartholini F, Casu MA, Ruiu S, Casti P, Congeddu E, Tambaro S, Pani L (2004a) Haloperidol versus risperidone on rat "early onset" vacuous chewing. Behav Brain Res 149:9-16
39. Marchese G, Bartholini F, Ruiu S, Casti P, Casu GL, Pani L (2004b) Ritanserin counteracts both rat vacuous chewing movements and nigro-striatal tyrosine hydroxylase-immunostaining alterations induced by haloperidol. Eur J Pharmacol 483:65-69
40. Masan PS (2004) Atypical antipsychotics in the treatment of affective symptoms: a review. Ann Clin Psychiatry 16:3-13
41. McIntyre RS, Mancini DA, Lin P, Jordan J (2004) Treating bipolar disorder. Evidence-based guidelines for family medicine. Can Fam Physician 50:388-394
42. i values. J Pharmacol Exp Ther 251:238-246
43. Muscettola G, Barbato G, Pampallona S, Casiello M, Bollini P (1999) Extrapyramidal syndromes in neuroleptic-treated patients: prevalence, risk factors, and association with tardive dyskinesia. J Clin Psychopharmacol 19:203-208
44. 2A receptor affinity. J Med Chem 38:28-33
45. Plech A, Brus R, Kalbfleisch JH, Kostrzewa RM (1995) Enhanced oral activity responses to intrastriatal SKF 38393 and m-CPP are attenuated by intrastriatal mianserin in neonatal 6-OHDA-lesioned rats. Psychopharmacology (Berl) 119:466-473
46. 2C receptors. Brain Res Mol Brain Res 23:163-178
47. 2C receptor antagonist. Br J Pharmacol 126:572-574
48. Rupniak NM, Jenner P, Marsden CD (1985) Pharmacological characterisation of spontaneous or drug-associated purposeless chew ing movements in rats. Psychopharmacology (Berl) 85:71-79
49. Rupniak NM, Jenner P, Marsden CD (1986) Acute dystonia induced by neuroleptic drugs. Psychopharmacology (Berl) 88:403-419
50. Salamone JD, Mayorga AJ, Trevitt JT, Cousins MS, Conlan A, Nawab A (1998) Tremulous jaw movements in rats: a model of parkinsonian tremor. Prog Neurobiol 56:591-611
51. Sanders-Bush E, Tsutsumi M, Burris KD (1990) Serotonin receptors and phosphatidylinositol turnover. Ann N Y Acad Sci 600:224-235 (discussion 235-6)
52. Steinpreis RE, Baskin P, Salamone JD (1993) Vacuous jaw movements induced by sub-chronic administration of haloperidol: interactions with scopolamine. Psychopharmacology (Berl) 111: 99-105
53. Stewart BR, Jenner P, Marsden CD (1988) The pharmacological characterisation of pilocarpine-induced purposeless chewing behaviour in the rat. Psychopharmacology (Berl) 96:55-62
54. Stockmeier CA, DiCarlo JJ, Zhang Y, Thompson P, Meltzer HY (1993) Characterization of typical and atypical antipsychotic drugs based on in vivo occupancy of serotonin2 and dopamine2 receptors. J Pharmacol Exp Ther 266:1374-1384
55. Tamminga CA (2003) The science of antipsychotics: mechanistic insight. CNS Spectr 8:5-9
56. Tariot PN, Profenno LA, Ismail MS (2004) Efficacy of atypical antipsychotics in elderly patients with dementia. J Clin Psychiatry 65(Suppl 11):11-15
57. Tarsy D, Baldessarini RJ, Tarazi FI (2002) Effects of newer antipsychotics on extrapyramidal function. CNS Drugs 16:23-45
58. Teitler M, Leonhardt S, Weisberg EL, Hoffman BJ (1990) 4-[125I] iodo-(2,5-dimethoxy)phenylisopropylamine and [3H]ketanserin labeling of 5-hydroxytryptamine2 (5HT2) receptors in mammalian cells transfected with a rat 5HT2 cDNA: evidence for multiple states and not multiple 5HT2 receptor subtypes. Mol Pharmacol 38:594-598
59. Tonda ME, Guthrie SK (1994) Treatment of acute neuroleptic-induced movement disorders. Pharmacotherapy 14:543-560
60. Turrone P, Remington G, Nobrega JN (2002) The vacuous chewing movement (VCM) model of tardive dyskinesia revisited: is there a relationship to dopamine D(2) receptor occupancy? Neurosci Biobehav Rev 26:361-380
61. Turrone P, Remington G, Kapur S, Nobrega JN (2003a) Differential effects of within-day continuous vs. transient dopamine D2 receptor occupancy in the development of vacuous chewing movements (VCMs) in rats. Neuropsychopharmacology 28:1433-1439
62. Turrone P, Remington G, Kapur S, Nobrega JN (2003b) The relationship between dopamine D2 receptor occupancy and the vacuous chewing movement syndrome in rats. Psychopharmacology (Berl) 165:166-171
63. Waddington JL (1990) Spontaneous orofacial movements induced in rodents by very long-term neuroleptic drug administration: phenomenology, pathophysiology and putative relationship to tardive dyskinesia. Psychopharmacology (Berl) 101:431-447
64. Wadenberg ML, Kapur S, Soliman A, Jones C, Vaccarino F (2000) Dopamine D2 receptor occupancy predicts catalepsy and the suppression of conditioned avoidance response behavior in rats. Psychopharmacology (Berl) 150:422-429
65. Wadenberg ML, Soliman A, VanderSpek SC, Kapur S (2001) Dopamine D(2) receptor occupancy is a common mechanism underlying animal models of antipsychotics and their clinical effects. Neuropsychopharmacology 25:633-641
66. 2C, and 5-HT6 with neuropeptides in rat striatum. J Comp Neurol 370:405-414
67. Wichmann T, DeLong MR (2003) Functional neuroanatomy of the basal ganglia in Parkinson's disease. Adv Neurol 91:9-18
68. 2C receptor is a prominent serotonin receptor in basal ganglia: evidence from functional studies on serotonin-mediated phosphoinositide hydrolysis. J Neurochem 69:1449-1458
69. 2C receptor antagonists: potential in schizophrenia. Drug Dev Res 54:88-94
70. Worrel JA, Marken PA, Beckman SE, Ruehter VL (2000) Atypical antipsychotic agents: a critical review. Am J Health-Syst Pharm 57:238-255